Managing abnormal blood fat levels is a journey that combines understanding your body’s unique needs, making informed lifestyle choices, and working closely with healthcare professionals to reduce the risk of serious heart and blood vessel problems.

Understanding the Path to Better Blood Fat Control

The approach to treating dyslipidaemia focuses on bringing abnormal levels of fats in your blood back into a healthier range. These fats, called lipids, include cholesterol and triglycerides that travel through your bloodstream. When these levels become too high or too low, they can gradually damage your blood vessels and increase the risk of heart attacks, strokes, and other cardiovascular problems. Treatment aims to lower dangerous LDL cholesterol levels, reduce triglycerides when needed, and sometimes raise protective HDL cholesterol.^[1]

The specific treatment plan depends heavily on several factors unique to each person. Doctors consider whether you already have heart disease, how high your cholesterol levels are, your age, whether you have diabetes or high blood pressure, and if you smoke. Someone who has already had a heart attack needs more aggressive treatment than someone who is simply trying to prevent problems from developing. Your overall cardiovascular risk determines how low your LDL cholesterol should be and whether lifestyle changes alone will be enough or if medications are necessary.^[9]

Medical guidelines from organizations like the National Cholesterol Education Program and the American Heart Association provide doctors with clear targets for blood fat levels. For people without existing heart disease but with one risk factor, the goal is typically to keep LDL cholesterol below 160 mg per deciliter. When someone has two or more risk factors, the target drops to below 130 mg/dL. For people who already have documented heart disease, the treatment goal becomes even stricter, with LDL cholesterol ideally below 100 mg/dL.^[9]

Treatment also varies depending on whether dyslipidaemia is primary or secondary. Primary dyslipidaemia is inherited, caused by genetic mutations that run in families and affect how the body processes fats. Secondary dyslipidaemia develops because of other conditions or lifestyle factors, such as obesity, diabetes, hypothyroidism, or excessive alcohol consumption. Before starting any treatment, doctors first rule out these secondary causes, as addressing the underlying condition may resolve the abnormal lipid levels.^[1]

Standard Medical Treatment for Dyslipidaemia

The cornerstone of classical dyslipidaemia treatment begins with lifestyle modifications, but when these are insufficient, several classes of medications have proven effective over decades of use. The most widely prescribed drugs are called statins, which work by blocking an enzyme called HMG-CoA reductase that the liver uses to produce cholesterol. By inhibiting this enzyme, statins reduce the amount of cholesterol manufactured in the body. Common statins include simvastatin, pravastatin, atorvastatin, and rosuvastatin.^[7]

Statins have been extensively studied and shown to significantly reduce the risk of heart attacks and deaths from cardiovascular disease. The Scandinavian Simvastatin Survival Study demonstrated a 30 percent reduction in total mortality among people with coronary heart disease who took simvastatin compared to those who did not. Another major trial found that pravastatin reduced LDL cholesterol by 26 percent and coronary events by 31 percent in people without prior heart disease. These medications are generally taken once daily, often in the evening, and treatment typically continues long-term.^[9]

Another important class of medications is bile acid-binding resins, which work in the digestive tract. These resins bind to bile acids in the intestine, forcing the liver to use more cholesterol to make new bile, thereby lowering blood cholesterol levels. Examples include cholestyramine and colesevelam. These medications are particularly useful for people who cannot tolerate statins or need additional cholesterol lowering beyond what statins provide alone.^[9]

Ezetimibe is a cholesterol absorption inhibitor that works by blocking the absorption of cholesterol from food in the small intestine. This medication is often combined with statins to achieve greater LDL cholesterol reduction than either drug alone. The combination of a high-dose statin with ezetimibe has become increasingly recommended, especially for people hospitalized with acute coronary syndrome.^[7]

For people with very high triglyceride levels, fibrates (also called fibric acid derivatives) are often prescribed. These medications work by activating specific receptors that regulate fat metabolism, leading to lower triglycerides and sometimes higher HDL cholesterol. Common fibrates include fenofibrate and gemfibrozil.^[9]

Nicotinic acid, also known as niacin, can lower LDL cholesterol and triglycerides while raising HDL cholesterol. It works through multiple mechanisms that affect how the liver produces and processes different types of fats. However, this medication can cause uncomfortable side effects like facial flushing, which limits its use in some people.^[9]

The duration of treatment with lipid-lowering medications is typically lifelong for most people. Dyslipidaemia is a chronic condition, and stopping medications usually results in cholesterol levels rising back to their previous high levels. Regular monitoring through blood tests is essential to ensure medications are achieving target levels and to watch for potential side effects. Doctors usually check lipid levels a few weeks after starting or adjusting medication, then every few months once levels are stable.^[14]

Innovative Treatments Being Tested in Clinical Trials

Beyond standard treatments, medical research has produced several promising new approaches to treating dyslipidaemia that are either recently approved or currently being studied in clinical trials. These innovative therapies work through different mechanisms than traditional medications and may help people who cannot reach their cholesterol goals with existing treatments or who experience intolerable side effects from statins.

One of the most significant advances involves PCSK9 inhibitors, a class of medications that includes evolocumab and alirocumab. These are injectable drugs that work by blocking a protein called PCSK9, which normally causes the breakdown of LDL receptors on liver cells. When PCSK9 is inhibited, more LDL receptors remain on the liver surface, allowing the liver to remove more LDL cholesterol from the blood. Clinical trials have shown these medications can lower LDL cholesterol by an additional 50 to 60 percent beyond what statins achieve alone.^[7]

The FOURIER trial, a major Phase III study, demonstrated that evolocumab significantly reduced cardiovascular events in people with existing heart disease. The study showed that achieving very low LDL cholesterol levels with this PCSK9 inhibitor was both safe and effective. These medications are administered as injections every two to four weeks and have proven particularly valuable for people with familial hypercholesterolemia, a genetic condition causing extremely high cholesterol levels that are difficult to control with statins alone.^[5]

Another innovative approach is inclisiran, a medication that uses a technology called small interfering RNA (siRNA) to reduce PCSK9 production at the genetic level. Unlike the PCSK9 inhibitor antibodies that block the protein after it is made, inclisiran prevents the protein from being produced in the first place. A remarkable advantage of this treatment is that it only needs to be administered twice yearly after initial loading doses, making it much more convenient than other injectable cholesterol medications. Clinical trials have shown that inclisiran can reduce LDL cholesterol by approximately 50 percent with an excellent safety profile.^[7]

Bempedoic acid represents another novel oral medication that inhibits cholesterol synthesis in the liver through a different pathway than statins. This drug works on an enzyme earlier in the cholesterol production pathway, specifically targeting ATP citrate lyase. An important advantage is that bempedoic acid does not cause muscle-related side effects, making it a valuable option for people who experienced muscle pain or weakness with statins. Clinical trials have demonstrated that bempedoic acid can lower LDL cholesterol by 15 to 25 percent and can be safely combined with statins and ezetimibe for even greater reductions.^[13]

For people with very high triglycerides, icosapent ethyl has emerged as an important treatment option. This is a highly purified form of omega-3 fatty acid (EPA) that has been shown in clinical trials to reduce cardiovascular events. The REDUCE-IT trial, a large Phase III study, found that icosapent ethyl reduced the risk of cardiovascular death, heart attack, and stroke by 25 percent in people with elevated triglycerides who were already taking statins. This medication works by reducing triglyceride production, decreasing inflammation in blood vessels, and stabilizing plaques in arteries.^[13]

Research into gene therapy approaches for familial hypercholesterolemia is also advancing. Scientists are investigating ways to correct or compensate for the genetic defects that cause inherited forms of high cholesterol. Some experimental approaches involve using viral vectors to deliver working copies of genes that produce LDL receptors. While these treatments remain in early phase clinical trials, they hold promise for people with severe genetic forms of dyslipidaemia who struggle to achieve adequate cholesterol control with current medications.^[7]

Clinical trials for these newer treatments typically follow a standard progression through three phases. Phase I trials test safety in small groups of healthy volunteers or patients, establishing whether the drug causes serious side effects and determining appropriate doses. Phase II trials expand to larger groups of people with the condition to evaluate whether the treatment actually works to lower cholesterol and continues to be safe. Phase III trials involve thousands of participants and compare the new treatment to existing standard treatments to determine if it provides additional benefits, particularly in reducing heart attacks, strokes, and death.^[13]

Many clinical trials for dyslipidaemia treatments are conducted internationally, with sites in the United States, Europe, and increasingly in other regions. Patient eligibility varies by study but typically includes requirements related to baseline cholesterol levels, presence or absence of cardiovascular disease, previous treatments tried, and absence of certain medical conditions that could interfere with the study. People interested in participating in clinical trials can discuss options with their doctors or search trial registries to find studies recruiting participants near them.

Most common treatment methods

• Lifestyle modifications
  • Following a heart-healthy eating pattern that is low in saturated fats (found in red meat, full-fat dairy products) and trans fats (in some margarines and baked goods)
  • Increasing intake of soluble fiber from foods like oatmeal, kidney beans, and whole grains to reduce cholesterol absorption
  • Eating foods rich in omega-3 fatty acids such as salmon, mackerel, walnuts, and flaxseeds
  • Regular physical exercise and activity to help raise HDL cholesterol and lower triglycerides
  • Weight loss for people who are overweight or obese
  • Limiting alcohol consumption to reduce triglyceride levels
• Statin therapy
  • HMG-CoA reductase inhibitors including simvastatin, pravastatin, atorvastatin, and rosuvastatin
  • Work by blocking cholesterol synthesis in the liver
  • Proven to reduce cardiovascular events and mortality in multiple large clinical trials
  • Generally taken once daily on a long-term basis
• Combination therapy
  • High-dose statin plus ezetimibe to achieve greater LDL cholesterol reduction
  • Statins combined with PCSK9 inhibitors for people with very high cardiovascular risk
  • Multiple medications targeting different mechanisms to reach treatment goals
• PCSK9 inhibitors
  • Injectable medications including evolocumab and alirocumab
  • Block a protein that breaks down LDL receptors, allowing more cholesterol removal from blood
  • Can lower LDL cholesterol by 50 to 60 percent beyond statin effects
  • Administered as injections every two to four weeks
  • Particularly useful for familial hypercholesterolemia and statin-intolerant patients
• Cholesterol absorption inhibitors
  • Ezetimibe blocks cholesterol absorption in the small intestine
  • Often combined with statins for additive effect
  • Provides additional LDL cholesterol lowering
• Fibrate therapy
  • Fibric acid derivatives like fenofibrate and gemfibrozil
  • Primarily used for high triglyceride levels
  • Work by activating receptors that regulate fat metabolism
  • Can also increase HDL cholesterol levels
• Novel RNA-based therapies
  • Inclisiran uses small interfering RNA technology to reduce PCSK9 production
  • Administered twice yearly after loading doses
  • Reduces LDL cholesterol by approximately 50 percent
  • Convenient dosing schedule improves treatment adherence
• ATP citrate lyase inhibitors
  • Bempedoic acid inhibits cholesterol synthesis through a different pathway than statins
  • Oral medication that does not cause muscle-related side effects
  • Can be combined safely with statins and ezetimibe
  • Reduces LDL cholesterol by 15 to 25 percent
• Omega-3 fatty acid therapy
  • Icosapent ethyl is a highly purified form of EPA
  • Reduces triglycerides and cardiovascular events in clinical trials
  • Works by decreasing triglyceride production and reducing inflammation
  • Used for people with elevated triglycerides already on statins